Jiangsu Nhwa Pharmaceutical posted 13% revenue and 10% net profit growth in 2024, driven by CNS drug leadership and increased R&D, while expanding digital health and launching new products. Dividend payout ratio reached 31.99%.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.